KRX to consider delisting original developer of disputed drug Invossa
IndustryJul 5, 2019
South Korea’s main bourse operator Korea Exchange (KRX) has designated Kolon TissueGene, original developer of the recently invalidated joint inflammation treatment Invossa, as a potential delisting target, officials said Friday.“A screening committee will be held within 15 working days (by July 26) to decide whether to delist (the company) or to grant a grace period for improvement,” KRX said in a public statement.Kolon TissueGene, the US affiliate of Kolon Life Science, went